Welcome to our dedicated page for Perrigo Co Plc SEC filings (Ticker: PRGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Perrigo Company plc (NYSE: PRGO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents filed with the Securities and Exchange Commission. Perrigo is incorporated in Ireland and files its reports as a foreign private issuer with ordinary shares listed on the New York Stock Exchange under the symbol PRGO.
Through its Form 8-K filings, Perrigo reports material events such as quarterly earnings releases, strategic reviews and significant transactions. Recent 8-Ks have furnished earnings results for its Consumer Self-Care Americas and Consumer Self-Care International segments, described non-GAAP measures such as adjusted operating income, adjusted diluted earnings per share, organic net sales and constant currency net sales, and outlined the items excluded in these non-GAAP metrics, including amortization of acquired intangibles, restructuring charges, unusual litigation, impairment charges, divestiture gains or losses and infant formula remediation.
Other 8-K filings detail corporate actions such as the entry into a Master Sale and Purchase Agreement to sell Perrigo’s Dermacosmetics branded business in Northern Europe, the Netherlands and Poland, and executive leadership changes and related compensation arrangements. These filings provide insight into how the company is managing its portfolio, capital allocation and organizational structure.
On Stock Titan, users can view Perrigo’s filings as they are made available from EDGAR and use AI-powered summaries to understand the main points of lengthy documents. This includes context around earnings-related disclosures, explanations of non-GAAP reconciliations and highlights from transaction agreements and governance updates. For investors tracking PRGO, this page serves as a centralized view of Perrigo’s regulatory reporting history and ongoing disclosure practices.
State Street Corporation reported beneficial ownership of 7,340,323 shares of Perrigo Co plc common stock, representing 5.3% of the class. The filing is a Schedule 13G and shows shared voting power of 6,531,899 and shared dispositive power of 7,340,323, with no sole voting or dispositive power reported. The submission names multiple State Street advisory subsidiaries as related entities and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.
Form 4 summary: Reporting person Patrick Lockwood-Taylor (Director; CEO) filed a Form 4 for PERRIGO Co plc (PRGO) reporting purchases on 08/08/2025.
Transactions: Ordinary shares acquired: 4,060 at $22.3682 (beneficial ownership after: 85,412); 346 at $22.38 (85,758); 54 at $22.37 (85,812). The form is signed by attorney-in-fact Diana Witt on 08/08/2025.
Perrigo Company plc — Quarterly highlights (Q2 ended June 28, 2025)
Net sales of $1,056.3M for the quarter and $2,100.2M for six months, down vs. prior year. Gross profit for the quarter was $362.9M. Operating income improved to $45.4M (vs. a loss of $26.5M a year ago); continuing operations reported a small loss of $0.5M for the quarter. Discontinued operations produced a loss of $7.9M, and diluted EPS was a loss of $0.06 for the quarter and $0.10 for six months.
Balance sheet and cash: cash and equivalents $454.2M (down $104.6M YTD); inventories increased to $1,215.5M. Total assets $10,094.1M; total liabilities $5,621.8M. Total borrowings outstanding $3,651.9M. Notable items: sale of Richard Bittner Business for $14.4M (pre-tax loss $1.6M); Prevacid impairment $1.5M; litigation accrual for price-fixing $30.0M with a 50% recovery receivable under indemnity (Altaris cap $50.0M). Foreign currency translation increased comprehensive income, producing comprehensive income of $137.0M for the quarter.
Perrigo Company plc (NYSE: PRGO) has signed a definitive Master Sale and Purchase Agreement dated 13 July 2025 to divest its Dermacosmetics branded business in Northern Europe, the Netherlands and Poland to Kairos Bidco AB, an investment vehicle managed by an affiliate of KKR. The transaction covers 100 % of the shares of Aco Hud Nordic AB and ancillary production, packaging and distribution assets.
Transaction economics: Kairos will pay €300 million in cash at closing, subject to customary working-capital, inventory, debt and cash adjustments. Perrigo is also eligible for up to €27 million of contingent consideration tied to performance milestones over a three-year period. Post-closing, Perrigo will provide transition services for a fee.
Timing & conditions: Closing is targeted for Q1 2026 and is contingent on (i) antitrust and other regulatory approvals, (ii) completion of agreed pre-closing restructurings, (iii) works-council consultations in certain jurisdictions and (iv) consummation of KKR’s separate acquisition of Karo Healthcare. Either party may terminate if the deal is not completed within 18 months.
Key covenants: Until closing, Perrigo must operate the Dermacosmetics business in the ordinary course, seek Kairos’s consent for certain actions, enter into non-compete and non-solicitation agreements, and continue marketing investment. Standard reps, warranties and indemnities apply; certain confidential schedules are omitted.
Strategic context: The sale further rationalises Perrigo’s portfolio after earlier divestitures (Rx, HRA Rare Diseases, Hospital & Specialty) and adds liquidity that can be redeployed toward core consumer-self-care operations or debt reduction. Management disclosed the deal via Form 8-K (Item 1.01) and a press release (Exhibit 99.1).
Perrigo Company plc (PRGO) – Form 4 insider filing: Executive Vice President & President of CSCI, Roberto Khoury, reported two transactions dated 8 July 2025.
- Disposition: Khoury disposed of 5,205 ordinary shares (Table I, coded “D”). No price information was supplied in the excerpt.
- Acquisition (equity award): He received 2,211 Restricted Stock Units (RSUs) (Table II, coded “A”). Each RSU converts to one ordinary share and vests in three equal annual instalments beginning 8 July 2026.
Following the transactions, Khoury directly owns the newly granted 2,211 RSUs; the filing does not disclose his remaining ownership of ordinary shares beyond the figures above. The activity is routine executive equity compensation combined with a modest share sale, providing limited insight into fundamental performance but useful for monitoring insider sentiment and potential dilution.
FAQ
What is the current stock price of Perrigo Co Plc (PRGO)?
What is the market cap of Perrigo Co Plc (PRGO)?
